ST-193 hydrochloride |
| Catalog No.GC34375 |
El clorhidrato de ST-193 es un potente inhibidor de arenavirus de amplio espectro; inhibe los virus Guanarito, JunÍn, Lassa y Machupo con valores de IC50 de 0.44, 0.62, 1.4 y 3.1 nM, respectivamente.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2320274-72-2
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
ST-193 hydrochloride is a potent broad-spectrum arenavirus inhibitor; inhibits Guanarito, Junin, Lassa and Machupo virus with IC50 values of 0.44, 0.62, 1.4 and 3.1 nM, respectively.
ST-193 inhibits LASV pseudotypes with an IC50 of 1.6 nM. ST-193 inhibits pseudotypes generated with other arenavirus envelopes as well, including the remaining four commonly associated with hemorrhagic fever (IC50s for Junín, Machupo, Guanarito, and Sabiá are in the 0.2 to 12 nM range) but exhibits no antiviral activity against pseudotypes incorporating either the GP from the LASV-related arenavirus lymphocytic choriomeningitis virus or the unrelated G protein from vesicular stomatitis virus, at concentrations of up to 10 μM[2].
ST-193 is found to be tolerated well when administered daily as an intraperitoneal injection of either 25 or 100 mg/kg/day for 14 days. ST-193-treated animals exhibit fewer signs of disease and enhance survival when compared to the ribavirin or vehicle groups. Body temperatures in all groups are elevated by day 9, but returned to normal by day 19 postinfection in the majority of ST-193-treated animals. ST-193 treatment mediates a 2- to 3-log reduction in viremia relative to vehicle-treated controls. The overall survival rate for the ST-193-treated guinea pigs is 62.5% (10/16) compared with 0% in the ribavirin (0/8) and vehicle (0/7) groups[3].
[1]. Burgeson JR, et al. Discovery and optimization of potent broad-spectrum arenavirus inhibitors derived from benzimidazole and related heterocycles. Bioorg Med Chem Lett. 2013 Feb 1;23(3):750-6. [2]. Larson RA, et al. Identification of a broad-spectrum arenavirus entry inhibitor. J Virol. 2008 Nov;82(21):10768-75. [3]. Cashman KA, et al. Evaluation of Lassa antiviral compound ST-193 in a guinea pig model. Antiviral Res. 2011 Apr;90(1):70-9.
Animal experiment: | Guinea pigs: ST-193 is formulated as a solution in 32% (w/v) 2-hydroxypropyl-β-cyclodextrin (HP-β-CD). Female Hartley guinea pigs are injected intraperitoneally with a 10 mg/mL solution of ST-193 at a volume of either 2.5 mL per kg of body weight (25 mg/kg) or 10 mL per kg (100 mg/kg). Four animals per dose are used, with blood samples collected from two animals per dose at each time point in alternating fashion. Blood samples are obtained at the indicated time points (4-24 h)[3]. |
References: [1]. Burgeson JR, et al. Discovery and optimization of potent broad-spectrum arenavirus inhibitors derived from benzimidazole and related heterocycles. Bioorg Med Chem Lett. 2013 Feb 1;23(3):750-6. | |
| Cas No. | 2320274-72-2 | SDF | |
| Canonical SMILES | CC(C1=CC=C(CNC2=CC=C3C(N=CN3C4=CC=C(OC)C=C4)=C2)C=C1)C.[H]Cl | ||
| Formula | C24H26ClN3O | M.Wt | 407.94 |
| Solubility | DMSO : ≥ 150 mg/mL (367.70 mM) | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.4513 mL | 12.2567 mL | 24.5134 mL |
| 5 mM | 0.4903 mL | 2.4513 mL | 4.9027 mL |
| 10 mM | 0.2451 mL | 1.2257 mL | 2.4513 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 9 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *